Explore Daewoong Pharmaceutical’s key research programs.
Pipeline Roadmap
Daewoong Pharmaceutical is steadily expanding its R&D pipeline across diverse therapeutic areas—including autoimmune diseases, metabolic disorders, fibrosis, and oncology—securing a wide range of promising drug candidates.
This strategic expansion continues to bolster our future competitiveness as we lead the global pharmaceutical market.
Discovery
Pre-clinical
Phase l
Phase ll
Phase lll
NDA
- * MASH (Metabolic Dysfunction-Associated Steatohepatitis)
- * IPF (Idiopathic Pulmonary Fibrosis)
- * SLE (Systemic Lupus Erythematosus)
- * NERD (Non-Erosive Reflux Disease)
- * ERD (Erosive Reflux Disease)